Finance

Cardiology devices maker reports new $20 million stock repurchase program

Published in Blood Weekly, March 9th, 2006

Thoratec Corporation (THOR), a world leader in products to treat cardiovascular disease, said that its board of directors has authorized a new stock repurchase program under which Thoratec common stock with a market value of up to $20 million may be acquired in the open market or in privately negotiated transactions.

The company has $5 million remaining in a $25 million stock repurchase program previously authorized by the company, which it intends to exhaust before utilizing the repurchase program newly authorized.

The number of shares to be purchased and the timing of such activity will be dependent on several conditions, including the price of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry